Open-label efficacy and safety trial of 42 days of 566C80 for Pneumocystis carinii pneumonia in AIDS patients.

Abstract

Pneumocystis carinii pneumonia continues to be a cause of morbidity and mortality in AIDS patients. Current therapies have a high rate of toxicity and failure. Compound 566C80 is a 1-4,hydroxynaphthoquinone with potent antiprotozoal activity which shows good efficacy and safety in 21-day treatment trials of P. carinii pneumonia (PCP) in AIDS patients. Because there is a generally high recurrence rate after treatment of PCP and there may be a possible advantage in decreasing the P. carinii burden in the lung with extended anti-Pneumocystis therapy, we performed an open label-trial of the safety and efficacy of 42-day therapy with 566C80 for PCP in AIDS patients. Ten patients were enrolled and one was lost to follow-up. Eight of the remaining nine patients successfully completed 42 days of therapy with minimal toxicity. This trial suggests that 566C80 for 42 days can be an effective, safe, and well-tolerated oral therapy for PCP in AIDS patients.

• Authors: M N Dohn, P T Frame, R P Baughman, S W Lafon, A G Smulian, P Caldwell, M D Rogers
• Journal: The Journal of protozoology (J Protozool) 1991 Nov-Dec Vol. 38 Issue 6 Pg. 220S-221S ISSN: 0022-3921 [Print] United States
• PMID: 1818178 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antifungal Agents
• Naphthoquinones
• Atovaquone

Topics

• Acquired Immunodeficiency Syndrome (complications)
• Administration, Oral
• Antifungal Agents (adverse effects, therapeutic use)
• Atovaquone
• Bronchoalveolar Lavage Fluid
• Drug Tolerance
• Follow-Up Studies
• Food
• Humans
• Male
• Naphthoquinones (adverse effects, therapeutic use)
• Pneumonia, Pneumocystis (complications, drug therapy)
• Recurrence
• Time Factors